Deliverables

D5.6 Work Package 5 Results of POC-phase 1 studies

The deliverable and its appendices are available at https://goo.gl/Cenaco.

D4.9 Work Package 4 White Paper: methods for vaccine benefit-risk monitoring, including vaccine coverage, safety and effectiveness

descargar documentación
or

D3.5 White paper: procedures for data access, sharing, linkage and integration, including privacy and ethics

descargar documentación
or

D4.4 Report on tested methods for accelerated assessment of vaccination coverage...

descargar documentación
or

D3.4 Catalogue and meta-profiles of data sources for vaccine benefit-risk monitoring

Overview of the AIRR instrument - The ADVANCE work package has been tasked to identify data sources in Europe that can potentially contribute to vaccine benefit-risk studies. In the process of achieving this aim, we developed the AIRR (ADVANCE...

descargar documentación
or

D3.3 Final Report on the Technical Requirements Analysis

Introduction - Work Package 3 (WP3) of the Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE) consortium is the WP involved with how to identify data sources for the rapid and integrated monitoring of benefit-risk...

descargar documentación
or

D 1.9 - Good Practice Guidance – Modules 1 and 3: Code of Conduct and Quality recommendations

EXECUTIVE SUMMARY Effective collaboration between stakeholders and governance for the conduct of studies are among the main objectives of ADVANCE. In this context, Work Package 1 will deliver a good practice guidance including core values to be...

descargar documentación
or

Deliverable 1.7: Analysis of key issues and gaps about perception and knowledge on benefits and risks of vaccines

EXECUTIVE SUMMARY As part of the IMI-ADVANCE project, a “Strategy for public communication in the context of vaccine benefit-risk monitoring” is to be developed (deliverable D.1.12.).A key element for the development of...

descargar documentación
or

D1.10 Final conceptual model for public-private interaction (“Good Practice Guidance Module 2: Governance models.”).

EXECUTIVE SUMMARY: The pandemic influenza season and the new pharmacovigilance legislation have changed the paradigm in Europe on how vaccines should be monitored in post marketing settings and how public and private stakeholders should interact to...

descargar documentación
or